Search

Displaying results 4341 - 4350 of 10000 in total
  1. Drug

    Fluprednisolone

    go.drugbank.com/drugs/DB09378
    Approved

    A synthetic glucocorticoid with anti-inflammatory properties.

    Categories: Corticosteroids for Systemic Use
  2. Drug

    ARCoV

    go.drugbank.com/drugs/DB15855
    Experimental

    Manufactured as a liquid, ARCoV is thermostable at room temperature for at least 1 week. … It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy

  3. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  4. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  5. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    Incadronate, or YM-175,[A202769] is a nitrogen containing bisphosphonate.

  6. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  7. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  8. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  9. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency

  10. Drug

    BMS-690514

    go.drugbank.com/drugs/DB11665
    Investigational

    BMS-690514 has been investigated for the treatment of Breast Cancer.